UPCOMING MILESTONES
Phase 2a topline data – H2 2023
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. We have built an attractive portfolio of assets and have a strong track record of drug discovery. Our drug discovery engine has delivered five molecules to clinical stage development, and we have completed a number of major partnering transactions in recent years. Our portfolio includes two Phase 2 assets; RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours and RXC007, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, as well as a pipeline of rapidly advancing research programs and collaborations, driven by our world-class drug discovery engine.
ROCK2 Selective Inhibitor
(RXC007)
Idiopathic pulmonary fibrosis (IPF)
Phase 2a topline data – H2 2023
GI-targeted ROCK Inhibitor
(RXC008)
Fibrostenotic Crohn’s Disease
IND/CTA submission – end 2023
Topline data – from H1 2023
Genetically selected pancreatic cancer monotherapy Biliary cancer monotherapy + anti-PD-1 combination
DDR Inhibitor
(Discoidin Domain Receptor)
Fibrosis, Cancer-associated fibrosis
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Wholly-owned)
Oncology & Fibrosis
Porcupine Inhibitor
(RXC006/AZD5055)
Idiopathic pulmonary fibrosis (IPF)
Licensed to AstraZeneca
MAPK Pathway
Target
Oncology
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
UPCOMING MILESTONES
Phase 2a topline data – H2 2023
UPCOMING MILESTONES
IND/CTA submission – end 2023
UPCOMING MILESTONES
Topline data – from H1 2023
UPCOMING MILESTONES
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Wholly-owned)
UPCOMING MILESTONES
Licensed to AstraZeneca
UPCOMING MILESTONES
Sold to Jazz Pharmaceuticals
MAPK Pathway
Target
UPCOMING MILESTONES
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
31-May-2023
Redx to Present at Jefferies Global Healthcare Conference in New York
17-May-2023
Interim Results for the Six Months Ended 31 March 2023
12-May-2023
Discovery of Pirtobrutinib Recognised with Plaque
11-May-2023
Redx Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models
At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.
Underpinning our work are our five core company values that underline in everything we do:
We stand or fall by quality data
The market waits for no-one
Bright ideas fuel our pipeline
We can’t win by giving up
Together we are stronger